Exercise of Options and Total Voting Rights

Destiny Pharma PLC

07 July 2023

 

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Exercise of Options and Total Voting Rights

Brighton, United Kingdom - 07 July 2023 - Destiny Pharma (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces that it has issued and allotted 7,946 new ordinary shares of 1 pence each in the capital of the Company (the "New Ordinary Shares") following an exercise of share options by an employee.

Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM, with dealings expected to commence on 12 July 2023 ("Admission").

Following Admission, the Company will have a total of 95,271,863 Ordinary Shares in issue. Shareholders may use this figure of 95,271,863 Ordinary Shares as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact:

Destiny Pharma plc
Debra Barker, CEO
Shaun Claydon, CFO
[phone]
[e-mail]

Optimum Strategic Communications 
Mary Clark / Nick Bastin / Manel Mateus / Eleanor Cooper
[phone]
[e-mail]

finnCap Ltd (Nominated Advisor and Joint Broker)
Geoff Nash / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
[phone]

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

[phone]

MC Services AG
Anne Hennecke / Andreas Burckhardt
[phone]

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2 clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COVTM, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects.

For further information on the company, please visit www.destinypharma.com

 

END